What Were Zentalis's (NASDAQ:ZNTL) Cash and R&D Figures in Q3 2026?

Sonal Goyal

10 November 2026 06:56 PM AEDT

What Were Zentalis's (NASDAQ:ZNTL) Cash and R&D Figures in Q3 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Cash, cash equivalents and marketable securities were $228.9 million at September 30, 2026.
Research and development expenses were $22.3 million for the third quarter of 2026.
The updated objective response rate in Cyclin E1-positive patients was 37.2%.
Median relative dose intensity was 84.6%.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) reported that cash, cash equivalents and marketable securities were $228.9 million as of September 30, 2026. The clinical-stage oncology company also reported Research and Development expenses of $22.3 million for the third quarter and an updated objective response rate of 37.2% in Cyclin E1-positive patients.

Cash Position

Cash, cash equivalents and marketable securities totaled $228.9 million at September 30, 2026, compared with the prior comparison date cited in the company's report. The company stated that this balance provides a runway into the first half of the following year, according to the company's Business update.

The company's cash figure is reported on its balance sheet.

Research and Development Expenses

Research and development expenses were $22.3 million for the three months ended September 30, 2026, compared with $23 million in the prior-year period. The company said the $0.7 million decrease was primarily attributable to a decrease of $6 million in expenses for certain studies that reached or are near completion.

Clinical Data

The company reported an updated objective response rate of 37.2% in response-evaluable Cyclin E1-positive patients, with a median duration of response that is reported in the company's data tables.

Median relative dose intensity was 84.6%, according to the company's update. Dose intensity measures the proportion of the planned dose that patients received.

Final Word

Zentalis reported cash, cash equivalents and marketable securities of $228.9 million at September 30, 2026, research and development expenses of $22.3 million, an updated objective response rate of 37.2% in Cyclin E1-positive patients, and median relative dose intensity of 84.6%.

FAQs

Q: How much cash did Zentalis report at September 30, 2026?

A: Cash, cash equivalents and marketable securities were $228.9 million.

Q: What were research and development expenses?

A: Research and development expenses were $22.3 million for the three months ended September 30, 2026.

Q: What was the objective response rate?

A: The updated objective response rate was 37.2% in response-evaluable Cyclin E1-positive patients.

Q: What was median relative dose intensity?

A: Median relative dose intensity was 84.6%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.